Medtronic plc and Pi-Cardia Ltd. announced on September 1, 2026 that Medtronic has made a strategic investment in the Israeli structural heart company. The collaboration secures an option for Medtronic to strengthen its structural heart portfolio around complex transcatheter aortic valve replacement procedures. The agreement highlights the growing importance of leaflet modification technologies in enabling safer valve-in-valve TAVR interventions.
ShortCut Device and Clinical Foundation
Pi-Cardia's ShortCut device is the first leaflet modification technology cleared by the United States Food and Drug Administration for use in patients at risk of coronary obstruction during valve-in-valve TAVR. The device is designed to help physicians split leaflets safely and reproducibly while preserving coronary access for future transcatheter procedures. In FDA-reviewed clinical studies, ShortCut achieved successful leaflet splitting in all pivotal trial patients and demonstrated a favorable safety profile.
Strategic Investment and Acquisition Option
Under the terms of the agreement, Medtronic will make strategic investments of up to $80 million into Pi-Cardia. Medtronic is expected to become the exclusive global commercial distributor of the ShortCut device beginning in 2027. The agreement also includes an option to acquire Pi-Cardia upon achievement of predefined milestones for an estimated upfront acquisition price of up to $210 million, plus additional potential earn-out payments.
Addressing a Growing Clinical Need
As transcatheter heart therapies continue to advance, more patients with complex anatomy are being considered for valve-in-valve TAVR procedures. Coronary obstruction is a serious procedural risk that can limit treatment options and compromise long-term patient outcomes. Leaflet modification technologies such as ShortCut are intended to address this challenge by enabling safer procedures and preserving future coronary access.
Leadership Perspectives on the Collaboration
Jorie Soskin, vice president and general manager of the Structural Heart business within Medtronic's Cardiovascular portfolio, said the company is investing in technologies that help physicians address current challenges while preparing for future opportunities. Soskin noted that Medtronic believes leaflet modification technologies like ShortCut have the potential to become an important component of structural heart care. The investment reflects a commitment to shaping the future of TAVR for patients with complex anatomy.
Pi-Cardia's Mission and Investor Support
Erez Golan, Chief Executive Officer of Pi-Cardia, stated that the company's mission has been to make leaflet modification a standard part of complex TAVR. He described Medtronic as the right partner to help achieve this vision given its global reach and commitment to innovative tools. Pi-Cardia was founded by Erez Golan and Eyal Kolka and is supported by medtech investors including Sofinnova Partners, Sprig Equity, and Jacques Séguin.
Future Impact and Strategic Fit
The strategic investment secures an option for Medtronic to add a first-of-its-kind technology that addresses a significant challenge in valve-in-valve TAVR. ShortCut complements Medtronic's existing leadership in transcatheter valve therapies and supports the company's long-term growth strategy. Partnering early with innovators reflects Medtronic's broader commitment to improving patient outcomes and expanding future treatment options.
Transaction Conditions and Regulatory Review
Medtronic and Pi-Cardia noted that the strategic investment and related distribution arrangement are subject to regulatory approval and customary closing conditions. The companies have not specified a definitive timeline for completion of the initial investment, but the exclusive distribution role is expected to begin in 2027. Further updates will likely depend on regulatory milestones and the achievement of predefined operational targets.
The collaboration represents a notable step forward for complex TAVR care, combining a proven leaflet modification device with Medtronic's global commercial infrastructure. It signals confidence in the long-term value of leaflet modification as a standard component of structural heart intervention. If milestones are met, the agreement could evolve into a full acquisition, potentially reshaping the structural heart market and expanding patient options worldwide.